54-97-7

Basic information

• Product Name: 2-Phenylcyclopropane-1-amine
• Synonyms: 1-Amino-2-phenylcyclopropane;2-Phenylcyclopropane-1-amine;2-Phenylcyclopropylamine;2-Phenylcyclopropan-1-amine;Cyclopropanamine, 2-phenyl-
• CAS NO: 54-97-7
• Molecular Formula: C₉H₁₁N
• Molecular Weight: 133.1903
• Mol File: 54-97-7.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 218.3 °C at 760 mmHg
• Flash Point: 90.8 °C
• Appearance: /
• Density: 1.065 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Phenylcyclopropane-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenylcyclopropane-1-amine(54-97-7)
• EPA Substance Registry System: 2-Phenylcyclopropane-1-amine(54-97-7)

Safety Data

• Hazardous Substances Data: 54-97-7(Hazardous Substances Data)

Usage

Uses

2-Phenylcyclopropanamine is a useful reagent for the preparation of preparation of oxadiazole derivatives as fungicides.

Upstream product

• 1036637-32-7 methyl (1S,2R)-1-nitro-2-phenylcyclopropanecarboxylate 
• 100-42-5 styrene 
• 874341-82-9 [(1S,2R)-2-nitrocyclopropyl]benzene 
• 110659-58-0 (1R,2R)-1-hydroxymethyl-2-phenylcyclopropane 
• 1521265-16-6 (1R,2S)-2-methoxy-N-(2-phenyl-cyclopropyl)-acetamide 
• 939-89-9 (1S*,2R*)-2-phenylcyclopropane-1-carboxylic acid 
• 14561-40-1 (+/-)-cis-2-phenyl-cyclopropane-carboxylic acid-⁽¹⁾-hydrazide 
• 5685-38-1 2-phenyl-cyclopropanecarboxylic acid 
• 928054-80-2 (-)-trans-2-phenylcyclopropanecarboxylic acid (2-hydroxy-1-phenylethyl)amide 
• 4192-77-2 ethyl cinnamate 
• 946-38-3 ethyl 2-phenylcyclopropylcarboxylate 
• 4407-36-7 (2E)-3-phenyl-2-propen-1-ol 
• 185256-47-7 (-)-(1R,2S)-trans (2-phenyl-cyclopropyl)carbaminic acid tert-butyl ester 
• 3471-10-1 (1R,2R)-trans-2-phenyl-1-cyclopropanecarboxylic acid 

Downstream Products

• 1006-66-2 5-phenyl-4,5-dihydroisoxazole 
• 132350-68-6 (2-Nitro-cyclopropyl)-benzene 
• 65-85-0 benzoic acid 
• 1351165-22-4 C₂₁H₂₂Cl₂N₄O₂ 
• 1351165-63-3 C₂₁H₂₂Cl₂N₄O₂ 
• 1211400-41-7 (8aS)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1R,2S)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-31-5 C₂₂H₂₅N₃O₃ 
• 1211400-32-6 (8aR)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1R,2S)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-18-8 C₂₂H₂₅N₃O₃ 
• 50584-02-6 trans-2-Benzamido-1-phenyl-cyclopropan 
• 1521265-14-4 (2S,3S,4S)-4-fluoro-3-methoxy-2-((1R,2S)-2-phenyl-cyclopropylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Synthetic method for arylcyclopropylamine compound

The invention relates to a synthetic method for an arylcyclopropylamine compound. The method comprises the following steps: with a cinnamaldehyde compound as a raw material, reacting the cinnamaldehyde compound with bis(pinacolato)diboron to obtain a boroalkylated product; and then subjecting the boroalkylated product and an aminated compound to a ring-closure reaction so as to obtain the arylcyclopropylamine compound. Compared with the prior art, the invention has the following advantages: the synthetic method of the invention is simple to operate and short in reaction time; reagents used inthe invention are cheap and easily available; the target arylcyclopropylamine compound can be prepared from most substrates at a high overall yield and is mainly in the form of transconfiguration; anda route of the method is obviously improved, more economical, safer and easy for industrial production.

Gram-Scale Synthesis of Chiral Cyclopropane-Containing Drugs and Drug Precursors with Engineered Myoglobin Catalysts Featuring Complementary Stereoselectivity

Engineered hemoproteins have recently emerged as promising systems for promoting asymmetric cyclopropanations, but variants featuring predictable, complementary stereoselectivity in these reactions have remained elusive. In this study, a rationally driven strategy was implemented and applied to engineer myoglobin variants capable of providing access to 1-carboxy-2-aryl-cyclopropanes with high trans-(1R,2R) selectivity and catalytic activity. The stereoselectivity of these cyclopropanation biocatalysts complements that of trans-(1S,2S)-selective variants developed here and previously. In combination with whole-cell biotransformations, these stereocomplementary biocatalysts enabled the multigram synthesis of the chiral cyclopropane core of four drugs (Tranylcypromine, Tasimelteon, Ticagrelor, and a TRPV1 inhibitor) in high yield and with excellent diastereo- and enantioselectivity (98–99.9% de; 96–99.9% ee). These biocatalytic strategies outperform currently available methods to produce these drugs.